Want to see ATRA full AI Analyst Report?
Top Page
Atara Biotherapeutics
(NASDAQ:ATRA)
Select Model
Select Model
Rating:49Neutral
Price Target:
$8.50
▼(-46.17% Downside)
Action:Reiterated
Date:06/13/26
The score is held down primarily by weak financial performance (sharp TTM revenue decline, return to losses, negative equity, and persistent cash burn). Technical indicators provide some support via improved trend and positive momentum, but valuation is constrained by negative earnings, and corporate events are mixed with regulatory progress offset by Nasdaq delisting-risk pressure.
Positive Factors
High Gross Margin
A sustained ~96% gross margin reflects favorable product economics for Atara's biologic/cell therapy technology. If clinical programs convert to commercial products or higher-margin partnered revenue, this structural advantage supports operating leverage and durable profitability as scale and revenues increase.
Negative Factors
Negative Shareholder Equity
Sustained negative equity indicates an impaired capital structure and cumulative losses that materially constrain financing flexibility. This increases insolvency and covenant risk, makes debt expensive or unavailable, and heightens reliance on dilutive equity raises or nonrecurring partnership payments to fund operations.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
A sustained ~96% gross margin reflects favorable product economics for Atara's biologic/cell therapy technology. If clinical programs convert to commercial products or higher-margin partnered revenue, this structural advantage supports operating leverage and durable profitability as scale and revenues increase.
Read all positive factors
Atara Biotherapeutics (ATRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$75.60M
Dividend YieldN/A
Average Volume (3M)83.42K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue Growth-88.41%
EPS Growth76.14%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.66
Shares Outstanding9,010,172
10 Day Avg. Volume98,715
30 Day Avg. Volume83,419
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-5.89
Price to Sales (P/S)1.88
P/FCF Ratio-4.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.67Price Target Upside-13.45% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.3
Revenue Forecast (FY)$2.11M
Atara Biotherapeutics Business Overview & Revenue Model
Company Description
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments...
How the Company Makes Money
Atara Biotherapeutics primarily generates revenue from collaboration arrangements rather than from recurring product sales, as its lead and other programs have been in development and its financial results have historically been driven by payments...
Atara Biotherapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
14
Very Negative
Cash Flow
9
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.14M | 120.77M | 128.94M | 8.57M | 63.57M | 20.34M |
| Gross Profit | 22.24M | 99.56M | 107.93M | -313.00K | -206.42M | -261.66M |
| EBITDA | -5.48M | 38.63M | -75.75M | -266.00M | -222.26M | -330.75M |
| Net Income | -9.47M | 32.69M | -85.40M | -276.13M | -228.30M | -340.14M |
Balance Sheet | ||||||
| Total Assets | 20.00M | 20.23M | 109.10M | 165.50M | 376.42M | 468.13M |
| Cash, Cash Equivalents and Short-Term Investments | 8.36M | 8.48M | 42.50M | 51.73M | 242.82M | 371.07M |
| Total Debt | 10.09M | 52.80M | 43.83M | 57.87M | 71.70M | 28.27M |
| Total Liabilities | 57.31M | 58.74M | 206.38M | 264.74M | 249.78M | 188.51M |
| Stockholders Equity | -37.31M | -38.50M | -97.28M | -99.23M | 126.64M | 279.61M |
Cash Flow | ||||||
| Free Cash Flow | -25.88M | -50.94M | -68.96M | -194.20M | -274.62M | -231.10M |
| Operating Cash Flow | -25.88M | -50.94M | -68.72M | -192.98M | -270.43M | -220.52M |
| Investing Cash Flow | 949.00K | 18.15M | 8.62M | 123.87M | 202.96M | 22.26M |
| Financing Cash Flow | 19.30M | 16.10M | 59.28M | 2.01M | 53.08M | 103.94M |
Atara Biotherapeutics Technical Analysis
Negative
15.79
Price Trends
9.83
Negative
7.48
Positive
9.76
Negative
Market Momentum
-0.33
Positive
39.26
Neutral
17.25
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATRA, the sentiment is Negative. The current price of 15.79 is above the 20-day moving average (MA) of 10.08, above the 50-day MA of 9.83, and above the 200-day MA of 9.76, indicating a bearish trend. The MACD of -0.33 indicates Positive momentum. The RSI at 39.26 is Neutral, neither overbought nor oversold. The STOCH value of 17.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATRA.
Atara Biotherapeutics Risk Analysis
Atara Biotherapeutics disclosed 73 risk factors in its most recent earnings report. Atara Biotherapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Atara Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $363.76M | -2.95 | -53.61% | ― | -100.00% | 44.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $75.60M | -12.71 | 25.68% | ― | -88.41% | 76.14% | |
49 Neutral | $285.40M | -4.08 | -147.80% | ― | 1.97% | -25.03% | |
45 Neutral | $254.96M | -0.53 | 309.79% | ― | -35.61% | -68.92% | |
44 Neutral | $59.78M | -0.95 | -91.94% | ― | 106.65% | 12.20% |
* Healthcare Sector Average
ATRA
Atara Biotherapeutics
8.39
-3.11
-27.04%
MGNX
MacroGenics
4.49
3.02
205.44%
ZNTL
Zentalis Pharmaceuticals
5.11
3.72
267.63%
SRZN
Surrozen
21.96
13.26
152.41%
TCRX
TScan Therapeutics
0.91
-0.92
-50.05%
Atara Biotherapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Atara Biotherapeutics Adds Independent Director to Board
Positive
Jun 12, 2026
On June 11, 2026, Atara Biotherapeutics appointed Brian Cherry as a Class I independent director and member of its Audit Committee, granting him 24,000 restricted stock units vesting over three years and standard non-employee director compensation...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Atara Biotherapeutics Gains Clearer FDA Path for Tab-cel
Positive
May 7, 2026
On May 7, 2026, Atara Biotherapeutics announced that partner Pierre Fabre Pharmaceuticals had a constructive Type A meeting with the U.S. Food and Drug Administration regarding the Complete Response Letter issued on January 9, 2026 for the Biologi...
Delistings and Listing ChangesRegulatory Filings and Compliance
Atara Biotherapeutics Receives Nasdaq Non-Compliance Delisting Notice
Negative
May 1, 2026
On April 30, 2026, Atara Biotherapeutics received notice from Nasdaq that it no longer meets the $50 million minimum market value of listed securities required for continued listing on the Nasdaq Global Select Market. The company has until October...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.